192 related articles for article (PubMed ID: 12034711)
21. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
Ellis V
J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
[TBL] [Abstract][Full Text] [Related]
22. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
Hillig T; Engelholm LH; Ingvarsen S; Madsen DH; Gårdsvoll H; Larsen JK; Ploug M; Danø K; Kjøller L; Behrendt N
J Biol Chem; 2008 May; 283(22):15217-23. PubMed ID: 18362146
[TBL] [Abstract][Full Text] [Related]
23. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
24. Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells.
Ploug M; Rahbek-Nielsen H; Nielsen PF; Roepstorff P; Dano K
J Biol Chem; 1998 May; 273(22):13933-43. PubMed ID: 9593742
[TBL] [Abstract][Full Text] [Related]
25. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
Mizukami IF; Todd RF
J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
[TBL] [Abstract][Full Text] [Related]
26. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
27. Novel interactions between urokinase and its receptor.
Shliom O; Huang M; Sachais B; Kuo A; Weisel JW; Nagaswami C; Nassar T; Bdeir K; Hiss E; Gawlak S; Harris S; Mazar A; Higazi AA
J Biol Chem; 2000 Aug; 275(32):24304-12. PubMed ID: 10801829
[TBL] [Abstract][Full Text] [Related]
28. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
29. Regulation of the uPAR/uPA system expressed on monocytes by the deactivating cytokines, IL-4, IL-10 and IL-13: consequences on cell adhesion to vitronectin and fibrinogen.
Paysant J; Vasse M; Soria J; Lenormand B; Pourtau J; Vannier JP; Soria C
Br J Haematol; 1998 Jan; 100(1):45-51. PubMed ID: 9450789
[TBL] [Abstract][Full Text] [Related]
30. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
[TBL] [Abstract][Full Text] [Related]
31. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
32. The kringle stabilizes urokinase binding to the urokinase receptor.
Bdeir K; Kuo A; Sachais BS; Rux AH; Bdeir Y; Mazar A; Higazi AA; Cines DB
Blood; 2003 Nov; 102(10):3600-8. PubMed ID: 12881310
[TBL] [Abstract][Full Text] [Related]
33. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Chang AW; Kuo A; Barnathan ES; Okada SS
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of the urokinase receptor in a ligand-free form.
Xu X; Gårdsvoll H; Yuan C; Lin L; Ploug M; Huang M
J Mol Biol; 2012 Mar; 416(5):629-41. PubMed ID: 22285761
[TBL] [Abstract][Full Text] [Related]
35. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
36. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells.
Simon DI; Rao NK; Xu H; Wei Y; Majdic O; Ronne E; Kobzik L; Chapman HA
Blood; 1996 Oct; 88(8):3185-94. PubMed ID: 8874219
[TBL] [Abstract][Full Text] [Related]
37. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
[TBL] [Abstract][Full Text] [Related]
38. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Stahl A; Mueller BM
Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
40. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.
Huai Q; Zhou A; Lin L; Mazar AP; Parry GC; Callahan J; Shaw DE; Furie B; Furie BC; Huang M
Nat Struct Mol Biol; 2008 Apr; 15(4):422-3. PubMed ID: 18376415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]